PRESS RELEASE
14 March 2022 08:00:00 CET

Egetis announces participation at upcoming conferences

Stockholm, Sweden, March 14, 2022 - Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that Nicklas Westerholm, CEO, will participate at the following upcoming conferences in March-May 2022:

Carnegie Virtual Nordic Healthcare Seminar
March 17, 2022: Presentation at 16:00-16:30 CET

Handelsbanken Triple H Event (virtual)
March 23, 2022

Kempen Life Sciences Conference, Amsterdam, The Netherlands
April 21, 2022

Redeye Theme: Orphan Drugs, Stockholm, Sweden
April 27, 2022

LSX World Congress, London, UK
May 11, 2022: Panel discussion 12:20-13:00 GMT 'Multi-Jurisdictional Drug Development'

ABG Sundal Collier Life Science Summit, Stockholm, Sweden
May 18-19, 2022

For further information, please contact:

Nicklas Westerholm, CEO
Tel. +46 (0) 733 542 062
nicklas.westerholm@egetis.com

Karl Hård, Head of Investor Relations & Communications
Tel. +46 (0) 733 011 944
karl.hard@egetis.com

PRESS RELEASE
14 March 2022 08:00:00 CET

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for treatment of serious diseases with significant unmet medical needs in the orphan drug segment. The drug candidate *Emcitate* is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. Triac Trial I (Phase IIb) and a long-term real-life study have been completed with clinically relevant and highly significant results on serum T3 concentrations and secondary clinical endpoints. Egetis intends to submit a marketing authorisation application for *Emcitate* to the European Medicines Agency in the first half of 2023 based on existing clinical data. As a result of fruitful FDA interactions, Egetis will conduct a randomized, placebo-controlled study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit an NDA in the US for *Emcitate* in mid-2023 under the Fast Track Designation granted by the FDA. *Emcitate* is currently being investigated in Triac Trial II, a Phase II/III study in very young MCT8 deficiency patients (<30 months of age) exploring potential disease modifying effects of early intervention from a neurocognitive and neurodevelopmental perspective. Results are expected in the first quarter of 2024 and is expected to be submitted post-approval to regulatory authorities shortly thereafter. *Emcitate* holds Orphan Drug Designation (ODD) in the US and EU and has been granted Rare Pediatric Disease Designation.
The drug candidate *Aladote* is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for *Aladote* has been finalized after completed interactions with FDA, EMA and MHRA. *Aladote* has been granted ODD in the US and an application for ODD was submitted in Europe in the first quarter of 2021. There is an ongoing dialogue with EMA on the appropriate indication for an ODD in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Attachments

Egetis announces participation at upcoming conferences